Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 08, 2023

BUY
$0.07 - $0.12 $12,099 - $20,742
172,850 Added 58.82%
466,688 $42,000
Q2 2023

Jul 20, 2023

BUY
$0.08 - $0.29 $10,328 - $37,439
129,100 Added 78.37%
293,838 $26,000
Q1 2023

May 09, 2023

BUY
$0.24 - $0.34 $13,032 - $18,462
54,300 Added 49.17%
164,738 $42,000
Q4 2022

Feb 14, 2023

BUY
$0.18 - $0.3 $11,376 - $18,960
63,200 Added 133.79%
110,438 $23,000
Q3 2022

Oct 27, 2022

BUY
$0.24 - $0.71 $2,496 - $7,384
10,400 Added 28.23%
47,238 $11,000
Q2 2022

Aug 09, 2022

SELL
$0.63 - $1.1 $9,313 - $16,262
-14,784 Reduced 28.64%
36,838 $26,000
Q1 2022

May 05, 2022

SELL
$0.72 - $1.2 $1,163 - $1,939
-1,616 Reduced 3.04%
51,622 $40,000
Q4 2021

Jan 25, 2022

SELL
$1.0 - $1.82 $11,750 - $21,385
-11,750 Reduced 18.08%
53,238 $53,000
Q3 2021

Oct 12, 2021

SELL
$1.53 - $1.85 $13,464 - $16,280
-8,800 Reduced 11.93%
64,988 $114,000
Q2 2021

Aug 05, 2021

BUY
$1.55 - $2.15 $15,166 - $21,037
9,785 Added 15.29%
73,788 $135,000
Q1 2021

May 06, 2021

BUY
$1.99 - $2.9 $22,043 - $32,123
11,077 Added 20.93%
64,003 $129,000
Q4 2020

Jan 21, 2021

SELL
$1.88 - $2.84 $23,268 - $35,150
-12,377 Reduced 18.95%
52,926 $113,000
Q3 2020

Oct 14, 2020

SELL
$2.69 - $4.95 $8,508 - $15,656
-3,163 Reduced 4.62%
65,303 $176,000
Q2 2020

Aug 13, 2020

BUY
$0.7 - $4.16 $33,556 - $199,422
47,938 Added 233.52%
68,466 $269,000
Q1 2020

Apr 17, 2020

SELL
$0.76 - $1.54 $2,736 - $5,544
-3,600 Reduced 14.92%
20,528 $15.6 Million
Q4 2019

Jan 13, 2020

BUY
$0.65 - $1.26 $8,326 - $16,140
12,810 Added 113.18%
24,128 $30,000
Q3 2019

Oct 07, 2019

SELL
$0.5 - $0.91 $4,050 - $7,371
-8,100 Reduced 41.71%
11,318 $8,000
Q2 2019

Jul 18, 2019

BUY
$0.62 - $3.6 $12,039 - $69,904
19,418 New
19,418 $11,000

Others Institutions Holding NAVB

About NAVIDEA BIOPHARMACEUTICALS, INC.


  • Ticker NAVB
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 32,150,900
  • Description
  • Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates through two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expr...
More about NAVB
Track This Portfolio

Track Allred Capital Management, LLC Portfolio

Follow Allred Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Allred Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Allred Capital Management, LLC with notifications on news.